Yama A. Abassi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Yama A. Abassi has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
Xiaobo Wang
ACEA Biosciences, Inc., San Diego, CA 92121, USA
7 shared publicationsXiao Xu
6 shared publicationsBiao Xi
ACEA Biosciences, Inc., San Diego, CA 92121, USA
4 shared publicationsNing Ke
ACEA Biosciences, 6779 Mesa Ridge Rd., San Diego, CA, 92121, USA
2 shared publicationsXiaoyu Zhang
ACEA Biosciences, Inc., San Diego, CA 92121, USA
2 shared publicationsAlexander Seiler
Roche Applied Science, Penzberg, Germany
1 shared publication
Latest Publications
- 23 December 2015
- Published by Springer Nature
- Vol. 1272, 215-226
Multidimensional GPCR Profiling and Screening Using Impedance-Based Label-Free and Real-Time Assay
GPCRs constitute one of the most sought-after targets in drug discovery because they are associated with conditions ranging from cardiovascular diseases, autoimmune diseases, inflammation, cancer, and diseases of the nervous system. Moreover, they are one of the most amenable targets for drug discovery because they can be modulated by small molecules, peptides, proteins, and antibodies. Therefore it may not come as a surprise that close to 40 % of the drugs that are currently on the market are targeting GPCRs. It has become evident that GPCR signaling is highly complex and may involve multiple or a subset of pathways depending on the interaction of a GPCR with an agonist or antagonist. It is imperative that any functional screening for GPCR activity integrates this complexity. In this assay protocol, we describe how the xCELLigence RTCA HT impedance-based platform which can be used for functional cell-based GPCR assays can be utilized for GPCR screening.
- 23 December 2015
- Published by Springer Nature
- Vol. 1272, 215-226
Multidimensional GPCR Profiling and Screening Using Impedance-Based Label-Free and Real-Time Assay
GPCRs constitute one of the most sought-after targets in drug discovery because they are associated with conditions ranging from cardiovascular diseases, autoimmune diseases, inflammation, cancer, and diseases of the nervous system. Moreover, they are one of the most amenable targets for drug discovery because they can be modulated by small molecules, peptides, proteins, and antibodies. Therefore it may not come as a surprise that close to 40 % of the drugs that are currently on the market are targeting GPCRs. It has become evident that GPCR signaling is highly complex and may involve multiple or a subset of pathways depending on the interaction of a GPCR with an agonist or antagonist. It is imperative that any functional screening for GPCR activity integrates this complexity. In this assay protocol, we describe how the xCELLigence RTCA HT impedance-based platform which can be used for functional cell-based GPCR assays can be utilized for GPCR screening.
- 1 August 2013
- Published by Elsevier in Toxicology Letters
- Vol. 221, S231-S232
Cellular impedance assay for prediction of QT prolongation induced by hERG and non-hERG channel modulators using human stem cell derived cardiomyocytes
- 1 August 2013
- Published by Elsevier in Toxicology Letters
- Vol. 221, S231-S232
Cellular impedance assay for prediction of QT prolongation induced by hERG and non-hERG channel modulators using human stem cell derived cardiomyocytes
- Open Access
- 12 August 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (5) , 1424-1441
Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment
BACKGROUND AND PURPOSE Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug discovery process. In this report, we investigate the utility of an impedance‐based microelectronic detection system in conjunction with mouse embryonic stem cell‐derived cardiomyocytes for assessment of compound risk in the drug discovery process.EXPERIMENTAL APPROACH Beating of cardiomyocytes was measured by a recently developed microelectronic‐based system using impedance readouts. We used mouse stem cell‐derived cardiomyocytes to obtain dose‐response profiles for over 60 compounds, including ion channel modulators, chronotropic/ionotropic agents, hERG trafficking inhibitors and drugs known to induce Torsades de Pointes arrhythmias.KEY RESULTS This system sensitively and quantitatively detected effects of modulators of cardiac function, including some compounds missed by electrophysiology. Pro‐arrhythmic compounds produced characteristic profiles reflecting arrhythmia, which can be used for identification of other pro‐arrhythmic compounds. The time series data can be used to identify compounds that induce arrhythmia by complex mechanisms such as inhibition of hERG channels trafficking. Furthermore, the time resolution allows for assessment of compounds that simultaneously affect both beating and viability of cardiomyocytes.CONCLUSIONS AND IMPLICATIONS Microelectronic monitoring of stem cell‐derived cardiomyocyte beating provides a high throughput, quantitative and predictive assay system that can be used for assessment of cardiac liability earlier in the drug discovery process. The convergence of stem cell technology with microelectronic monitoring should facilitate cardiac safety assessment.
- 12 August 2011
- Published by Wiley in British Journal of Pharmacology
- Vol. 165 (5) , 1424-1441
Open AccessDynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment
BACKGROUND AND PURPOSE Cardiac toxicity is a major concern in drug development and it is imperative that clinical candidates are thoroughly tested for adverse effects earlier in the drug discovery process. In this report, we investigate the utility of an impedance‐based microelectronic detection system in conjunction with mouse embryonic stem cell‐derived cardiomyocytes for assessment of compound risk in the drug discovery process.EXPERIMENTAL APPROACH Beating of cardiomyocytes was measured by a recently developed microelectronic‐based system using impedance readouts. We used mouse stem cell‐derived cardiomyocytes to obtain dose‐response profiles for over 60 compounds, including ion channel modulators, chronotropic/ionotropic agents, hERG trafficking inhibitors and drugs known to induce Torsades de Pointes arrhythmias.KEY RESULTS This system sensitively and quantitatively detected effects of modulators of cardiac function, including some compounds missed by electrophysiology. Pro‐arrhythmic compounds produced characteristic profiles reflecting arrhythmia, which can be used for identification of other pro‐arrhythmic compounds. The time series data can be used to identify compounds that induce arrhythmia by complex mechanisms such as inhibition of hERG channels trafficking. Furthermore, the time resolution allows for assessment of compounds that simultaneously affect both beating and viability of cardiomyocytes.CONCLUSIONS AND IMPLICATIONS Microelectronic monitoring of stem cell‐derived cardiomyocyte beating provides a high throughput, quantitative and predictive assay system that can be used for assessment of cardiac liability earlier in the drug discovery process. The convergence of stem cell technology with microelectronic monitoring should facilitate cardiac safety assessment.
- 9 March 2011
- Published by Springer Nature
- Vol. 740, 33-43
The xCELLigence System for Real-Time and Label-Free Monitoring of Cell Viability
We describe here the use of the xCELLigence system for label-free and real-time monitoring of cell viability. The xCELLigence system uses specially designed microtiter plates containing interdigitated gold microelectrodes to noninvasively monitor the viability of cultured cells using electrical impedance as the readout. The continuous monitoring of cell viability by the xCELLigence system makes it possible to distinguish between different perturbations of cell viability, such as senescence, cell toxicity (cell death), and reduced proliferation (cell cycle arrest). In addition, the time resolution of the xCELLigence system allows for the determination of optimal time points to perform standard cell viability assays as well as other end-point assays to understand the mode of action. We have used the WST-1 assay (end-point viability readout), the cell index determination (continuous monitoring of viability by xCELLigence), and the DNA fragmentation assay (end-point apoptosis assay) to systematically examine cytotoxic effects triggered by two cytotoxic compounds with different cell-killing kinetics. Good correlation was observed for viability readouts between WST-1 and cell index. The significance of time resolution by xCELLigence readout is exemplified by its ability to pinpoint the optimal time points for conducting end point viability and apoptosis assays.
- 9 March 2011
- Published by Springer Nature
- Vol. 740, 33-43
The xCELLigence System for Real-Time and Label-Free Monitoring of Cell Viability
We describe here the use of the xCELLigence system for label-free and real-time monitoring of cell viability. The xCELLigence system uses specially designed microtiter plates containing interdigitated gold microelectrodes to noninvasively monitor the viability of cultured cells using electrical impedance as the readout. The continuous monitoring of cell viability by the xCELLigence system makes it possible to distinguish between different perturbations of cell viability, such as senescence, cell toxicity (cell death), and reduced proliferation (cell cycle arrest). In addition, the time resolution of the xCELLigence system allows for the determination of optimal time points to perform standard cell viability assays as well as other end-point assays to understand the mode of action. We have used the WST-1 assay (end-point viability readout), the cell index determination (continuous monitoring of viability by xCELLigence), and the DNA fragmentation assay (end-point apoptosis assay) to systematically examine cytotoxic effects triggered by two cytotoxic compounds with different cell-killing kinetics. Good correlation was observed for viability readouts between WST-1 and cell index. The significance of time resolution by xCELLigence readout is exemplified by its ability to pinpoint the optimal time points for conducting end point viability and apoptosis assays.
- 1 July 2009
- Published by Elsevier in Chemistry & Biology
- Vol. 16 (7) , 712-723
Kinetic Cell-Based Morphological Screening: Prediction of Mechanism of Compound Action and Off-Target Effects
- 1 July 2009
- Published by Elsevier in Chemistry & Biology
- Vol. 16 (7) , 712-723
Kinetic Cell-Based Morphological Screening: Prediction of Mechanism of Compound Action and Off-Target Effects
- 15 April 2008
- Published by Wiley in Biotechnology Journal
- Vol. 3 (4) , 484-495
The application of cell‐based label‐free technology in drug discovery
Cell‐based assays are an important part of the drug discovery process allowing for interrogation of targets and pathways in a more physiological setting compared to biochemical assays. One of the main hurdles in the cell‐based assay field is to design sufficiently robust assays with adequate signal to noise parameters while maintaining the inherent physiology of the pathway or target being investigated. Conventional label and reporter‐based cell assays may be more prone to artifacts due to considerable manipulation of the cell either by the label or over‐expression of targets or reporter proteins. Cell‐based label‐free technologies preclude the need for cellular labeling or over‐expression of reporter proteins, utilizing the inherent morphological and adhesive characteristics of the cell as a physiologically relevant and quantitative readout for various cellular assays. Furthermore, these technologies utilize non‐invasive measurements allowing for time resolution and kinetics in the assay. In this article, we have reviewed the various label‐free technologies that are being used in drug discovery settings and have focused our discussion on impedance‐based label‐free technologies and its main applications in drug discovery.
- 15 April 2008
- Published by Wiley in Biotechnology Journal
- Vol. 3 (4) , 484-495
The application of cell‐based label‐free technology in drug discovery
Cell‐based assays are an important part of the drug discovery process allowing for interrogation of targets and pathways in a more physiological setting compared to biochemical assays. One of the main hurdles in the cell‐based assay field is to design sufficiently robust assays with adequate signal to noise parameters while maintaining the inherent physiology of the pathway or target being investigated. Conventional label and reporter‐based cell assays may be more prone to artifacts due to considerable manipulation of the cell either by the label or over‐expression of targets or reporter proteins. Cell‐based label‐free technologies preclude the need for cellular labeling or over‐expression of reporter proteins, utilizing the inherent morphological and adhesive characteristics of the cell as a physiologically relevant and quantitative readout for various cellular assays. Furthermore, these technologies utilize non‐invasive measurements allowing for time resolution and kinetics in the assay. In this article, we have reviewed the various label‐free technologies that are being used in drug discovery settings and have focused our discussion on impedance‐based label‐free technologies and its main applications in drug discovery.
- 1 September 2004
- Published by Elsevier in Journal of Immunological Methods
- Vol. 292 (1-2) , 195-205
Label-free, real-time monitoring of IgE-mediated mast cell activation on microelectronic cell sensor arrays
- 1 September 2004
- Published by Elsevier in Journal of Immunological Methods
- Vol. 292 (1-2) , 195-205
Label-free, real-time monitoring of IgE-mediated mast cell activation on microelectronic cell sensor arrays